

Scientific Programme

Thursday 20 February 2025

Cholangiocarcinoma Day Session

Plenary

Chairs:
Rocio MACIAS, *Spain*
Grainne O'KANE, *Ireland*

- 11:00 - 11:10 **Welcome**
- 11:10 - 11:20 **Lancet**
Ivana NEDIC, *Spain*
- 11:20 - 11:35 **Epidemiology of CCA in Europe**
Lorenza RIMASSA, *Italy*
- 11:35 - 11:50 **Access to systemic treatment of CCA in Europe**
Chiara BRACONI, *United Kingdom*
- 11:50 - 12:05 **Palliative management of malignant bile duct strictures**
Wim LALEMAN, *Belgium*
- 12:05 - 12:20 **Diagnostic approach/Theranostic Molecular biology**
Grainne O'KANE, *Ireland*
- 12:20 - 12:30 **Panel Discussion**

Highlights of the EASL CPGs on hepatocellular carcinoma

Plenary

Chairs:
Bruno SANGRO, *Spain*

- 13:00 - 13:10 **Imaging**
Bruno SANGRO, *Spain*
- 13:10 - 13:15 **Pathology**
Valérie PARADIS, *France*
- 13:15 - 13:25 **Surgery**
Vincenzo MAZZAFERRO, *Italy*
- 13:25 - 13:35 **LRTs**
Tim MEYER, *United Kingdom*
- 13:35 - 13:45 **Systemic**
María REIG, *Spain*
- 13:45 - 14:00 **Q&A**

Innovations in the study of liver cancers pathogenesis

Plenary

Chairs:

Julien CALDERARO, *France*

Anna SABOROWSKI, *Germany*

14:30 - 14:50

Spatial biology

Stefano CARUSO, *France*

14:50 - 15:10

In situ Proteomics

Valérie PARADIS, *France*

15:10 - 15:20

Genetic predisposition

Luca VALENTI, *Italy*

15:20 - 15:30

Intratumor heterogeneity is conserved in single cell-derived hepatocellular carcinoma organoids

Lukas KÜBLER, *Switzerland*

15:30 - 15:45

Panel Discussion

Rare liver tumours

Plenary

Chairs:

Anna SABOROWSKI, *Germany*

María REIG, *Spain*

17:30 - 17:50

Diagnosis of rare liver tumours

Tania ROSKAMS, *Belgium*

17:50 - 18:05

Pediatric/Hepatoblastoma

Jessica ZUCMAN-ROSSI, *France*

18:05 - 18:20

Molecular biology of rare liver cancers and therapeutic implications

Jean Charles NAULT, *France*

18:20 - 18:30

The tumor suppressor miR-122 regulates liver cancer stem cells immune evasion and proliferation through CD24

Nofar ROSENBERG, *Israel*

18:30 - 18:40

Effect of Protease-Activated Receptor 2 inhibition by 1-Piperidinepropionic acid in lipid accumulation, inflammation and hepatocellular carcinoma development

Pietro GUERRA, *Italy*

18:40 - 19:00

Panel Discussion

Li - RADS system: benefits and limitations

Plenary

Chairs:

Fabio PISCAGLIA, *Italy*

Jens RICKE, *Germany*

19:00 - 19:10

LI-RADS system for lesions at risk of HCC. Benefits
Joanna PODGORSKA, *Poland*

19:10 - 19:20

LI-RADS system for lesions at risk of HCC. Limitations
Jordi BRUIX, *Spain*

19:20 - 19:30

Debate and take home message for the daily practice

Friday 21 February 2025

Round Table on Systemic therapy for HCC		Plenary
	Chairs: Fabio PISCAGLIA, <i>Italy</i> Radu VIDRA, <i>Romania</i>	
08:30 - 09:00	Case 1	
	Umberto Cillo, María Reig, Jens Ricke, Tim Meyer, Anna Saborowski, Giuliana Amaddeo, Gerda Elisabeth Villadsen	
09:00 - 09:30	Case 2	
	Umberto Cillo, María Reig, Jens Ricke, Tim Meyer, Anna Saborowski, Giuliana Amaddeo, Gerda Elisabeth Villadsen	
09:30 - 09:40	The role of a 13-serum-protein signature reflecting inflamed class hepatocellular carcinoma in patients receiving medical therapies	
	Ranjeet SINGH, <i>United Kingdom</i>	
09:40 - 09:50	A comprehensive evaluation of immune infiltration in hepatocellular carcinoma treated with liver surgery after selective internal radiation therapy	
	Maria Stella FRANZÈ, <i>Italy</i>	
09:50 - 10:00	Subsequent anticancer therapy analysis of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma	
	Ghassan ABOU-ALFA, <i>United States</i>	
10:00 - 10:10	A holistic approach of systematic tumor and non-tumor biopsy during percutaneous radiofrequency ablation for hepatocellular carcinoma: diagnostic, prognostic and therapeutic impact	
	Lorraine BLAISE, <i>France</i>	

State of the Art: Landscape of Cholangiocarcinoma Treatment		Plenary
	Chairs: Lorenza RIMASSA, <i>Italy</i> Chiara BRACONI, <i>United Kingdom</i>	
11:15 - 11:45	State of the Art: Landscape of Cholangiocarcinoma Treatment	
	Arndt VOGEL, <i>Canada</i>	

Systemic therapy: challenges/ difficult cases		Plenary
	Chairs: Lorenza RIMASSA, <i>Italy</i> Chiara BRACONI, <i>United Kingdom</i>	
11:45 - 12:10	Systemic therapy: challenges/ difficult cases	
	Angela LAMARCA, <i>Spain</i>	

- 12:10 - 12:20 **Should liver transplantation be considered for resectable perihilar cholangiocarcinoma? Preliminary results from the TRANSPHIL french randomized controlled trial**
Emmanuel BOLESZLAWSKI, *France*
- 12:20 - 12:30 **Mutational analysis of bile cell-free dna in primary sclerosing cholangitis: a pilot study**
Maria ARECHEDERRA, *Spain*

YI Poster Tour

Poster Tour

- Chairs:
Pedro RODRIGUES,
Carolin V. SCHNEIDER, *Germany*
- 14:00 - 14:05 **PO2-12-YI Impact of molecular alterations on outcomes of advanced biliary tract cancers treated with cisplatin, gemcitabine, and durvalumab: a multicenter, real-world study across Europe, Asia, and America**
Federico ROSSARI, *Italy*
- 14:05 - 14:10 **PO1-07-YI In-situ vaccination with Flt3L elicits immune responses against hepatocellular carcinoma and synergizes with checkpoint blockade therapy**
Isabella LURJE, *Germany*
- 14:10 - 14:15 **PO2-21-YI The alpha-1 Pi*^{MZ} genotype is an independent risk factor for hepatocellular carcinoma development in patients with advanced chronic liver disease**
Lorenz BALCAR, *Austria*
- 14:15 - 14:20 **PO1-08-YI Therapeutic potential of targeting Processing-bodies in Metabolic Dysfunction-Associated Steatohepatitis and hepatocellular carcinoma**
Noémie GELLÉE, *France*
- 14:20 - 14:25 **PO1-10-YI Manipulating tumour associated macrophages to elicit anticancer effects in a spheroid-engrafted precision-cut liver slice model of human hepatocellular carcinoma**
Amy COLLINS, *United Kingdom*
- 14:25 - 14:30 **PO2-17-YI Breaking Barriers for Intensive Care Admission in Patients with Advanced HCC on Immunotherapy**
Marta FORTUNY, *Spain*

Experimental models of liver cancer

Plenary

- Chairs:
Valérie PARADIS, *France*
Luke BOULTER, *United Kingdom*
- 14:30 - 14:45 **Experimental models: PDX, organoids**
Tian TIAN, *Spain*
- 14:45 - 15:00 **Experimental models: organs on a chip**
Ana LLEO, *Italy*

15:00 - 15:15 **Experimental models: animal models**
Luke BOULTER, *United Kingdom*

15:15 - 15:30 **Panel Discussion**

Artificial intelligence for management and research of liver cancers

Plenary

Chairs:

Julien CALDERARO, *France*

Raquel PÉREZ-LÓPEZ, *Spain*

17:15 - 17:30 **AI for investigation of clinical records**
Ashley SPANN, *United States*

17:30 - 17:45 **Radiomics of liver cancer: where are we now?**
Raquel PÉREZ-LÓPEZ, *Spain*

17:45 - 18:00 **European Union proposals to overcome current hurdles for clinical research**
Giacomo CAPONE, *Belgium*

18:00 - 18:15 **AI for liver research: what's next?**
Jakob Nikolas KATHER, *Germany*

18:15 - 18:30 **Uncertainty in AI models**
Federico CABITZA, *Italy*

18:30 - 18:45 **Panel Discussion**

Saturday 22 February 2025

Multidisciplinary care of liver cancer patients

Plenary

Chairs:
Rocio MACIAS, *Spain*
Ana LLEO, *Italy*

- 08:30 - 08:45 **Patient perspective of liver cancer management**
Helen MOREMENT, *United Kingdom*
- 08:45 - 09:00 **Management of liver cancer patients: extent of involvement of the nurse**
Sabita MAHARAJ, *United Kingdom*
- 09:00 - 09:15 **Management of adverse events**
Massimo IAVARONE, *Italy*
- 09:15 - 09:30 **Understanding the impact of Clinical Nurse Specialist led holistic needs assessment on patient's cancer journey and care planning for patients with Hepatocellular Carcinoma**
Sarah SELEMANI, *United Kingdom*
- 09:30 - 09:45 **Panel Discussion**

Abstract session:Advances in Liver Cancer Research

Plenary

Chairs:
Stefano CARUSO, *France*
Rocio MACIAS, *Spain*

- 10:45 - 10:55 **Modulating Wnt/"beta"-catenin pathway activity as a potential chemosensitive strategy in cholangiocarcinoma**
Kevin DELGADO-CALVO, *Spain*
- 10:55 - 11:05 **Sushi domain containing 2 upregulation in fibrotic Liver Disease: Potential role in hepatocellular carcinoma progression through Interaction with galectin-1**
Zaira REHMAN, *United Kingdom*
- 11:05 - 11:15 **Preliminary results on the utility of the GAAD algorithm for hepatocellular carcinoma screening in a prospective cohort of at-risk patients**
Emily LARREA, *Spain*
- 11:15 - 11:25 **Novel "3-in-1" blood metabolomic test for the early diagnosis and risk stratification of primary sclerosing cholangitis and cholangiocarcinoma**
Ainhoa LAPITZ, *Spain*
- 11:25 - 11:35 **Exploring the tumor immune microenvironment in cholangiocarcinoma: a spatial profiling using multiplex immunohistochemistry**
Dawei YI, *Germany*
- 11:35 - 11:45 **Discussion**

Chairs:

María REIG, *Spain*

Bruno SANGRO, *Spain*

12:15 - 12:30

New approaches and treatments to treat liver cancer

Pablo SAROBE, *Spain*

12:30 - 12:45

Superdowstaging to liver transplantation: is there really a clinical benefit?

Vincenzo MAZZAFERRO, *Italy*

12:45 - 13:00

Panel Discussion

13:00 - 13:15

Closing

Poster sessions

Thursday 20 February 2025

ePoster session 1

ePoster Area

12:30 - 13:00

Selective targeting of class I histone deacetylases with new derivatives of ursodeoxycholic acid as a novel treatment strategy for bile duct cancer
Francisco Javier CABALLERO-CAMINO, *Spain*

Spatial transcriptomic profiling reveals distinct stromal and clonal dynamics in liver cancer
Ji-Hye CHOI, *Korea, Rep. of South*

Activated Gold-Nanoparticles enhance PD-1 blockade and boost cytotoxic T cell anti-tumor responses in cholangiocarcinoma
Mirko MININI, *France*

An immature neutrophil signature associated with response to transarterial chemoembolization
Salem NIZAMI, *United Kingdom*

BAP1 mutations reveal a subgroup of BTC with distinct prognosis and benefit from adjuvant therapy: a retrospective biomarker analysis externally validated in a reconstructed global cohort
Antonella CAMMAROTA, *Italy*

Targeting UBE2I-mediated protein hyper-SUMOylation halts cholangiocarcinoma progression and rewires the tumor-stroma crosstalk
Irene OLAIZOLA, *Spain*

In-situ vaccination with Flt3L elicits immune responses against hepatocellular carcinoma and synergizes with checkpoint blockade therapy
Isabella LURJE, *Germany*

Therapeutic potential of targeting Processing-bodies in Metabolic Dysfunction-Associated Steatohepatitis and hepatocellular carcinoma
Noémie GELLÉE, *France*

Role of the splicing factor poly(rC)-binding protein 2 in cholangiocarcinoma malignancy and chemoresistance
Maria REVIEJO, *Spain*

Manipulating tumour associated macrophages to elicit anticancer effects in a spheroid-engrafted precision-cut liver slice model of human hepatocellular carcinoma
Amy COLLINS, *United Kingdom*

Therapeutic potential of Human antigen R inhibition in chronic liver disease and hepatocellular carcinoma
Mickaël JOUVE, *France*

Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma
Maidier HUICI IZAGIRRE, *Spain*

Molecular characterization of hemochromatosis tumors and iron overload in hepatocellular carcinoma

Patricia DE LA CRUZ-OJEDA, *France*

Therapeutic Targeting of Neddylation in Hepatoblastoma: Novel Approaches in Pediatric Liver Cancer

Leidy Estefanía ZAPATA-PAVAS, *Spain*

Lipid and cell cycling perturbations driven by the HDAC inhibitor romidepsin render liver cancer vulnerable to receptor tyrosine kinase targeting and immunologically active

Celia SEQUERA, *France*

Exploring the impact of mitochondrial biomarkers on HCC risk according to etiologic drivers: a multicenter study

Annalisa CESPIATI, *Italy*

ATR, guardian of genome integrity, a new player to optimize high replication stress hepatocarcinoma therapy

Jing FANG, *France*

The usefulness of novel cholangiocarcinoma cell lines with enhanced resistance to cisplatin or 5-fluorouracil to study mechanisms of chemoresistance

Kevin DELGADO-CALVO, *Spain*

Antitumoral activity of G9a inhibitors in hepatocellular carcinoma and its potential combination with immune checkpoint inhibitors

Maite G FERNANDEZ-BARRENA, *Spain*

Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments

Frederic SALTEL, *France*

Analysis of intrahepatic cccDNA and HBV-DNA in patients with hepatocellular carcinoma attributed to non-HBV etiologies

Beatriz MINGUEZ, *Spain*

Shaping the immune microenvironment of hepatocellular carcinoma tumours: a role for senescent endothelial cells

Daniel PATTEN, *United Kingdom*

Spatial transcriptomics characterization of liver microenvironment in MASH and MetALD HCCs

Yasmina CHOUIK, *France*

Thursday 20 February 2025

ePoster session 2

ePoster Area

14:00 - 14:30

The Role of FOXO1 in Post-Transplant Recurrence of Hepatocellular Carcinoma: A Study on Diagnostic and Therapeutic Targets

xiao XU, *China*

Molecular Phenotypic Linkage Between N6-methyladenosine Methylation and Tumor Immune Microenvironment in Hepatocellular Carcinoma

Feng ZHANG, *China*

Harnessing human immune system mouse models to validate NOX1 inhibition as a treatment for hepatocellular carcinoma

Zenzi DE VOS, *Belgium*

Deciphering the Glycosylation Status of Programmed Cell Death Ligand 1 and its regulation by Aurora Kinase A in Hepatocellular Carcinoma

Clarissa Joy GARCIA, *Italy*

Characterization of SLU7 silencing as a new strategy to treat cancer

Carla ROJO, *Spain*

A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab

Mara PERSANO, *Italy*

Novel chemotherapy selectively induces double-strand DNA breaks and death in naïve and Cisplatin-resistant cholangiocarcinoma tumours

Irene OLAIZOLA, *Spain*

Optimising an ex-vivo pre-clinical model of hepatocellular carcinoma (precision cut tumour slices) to study tumour biology and drug sensitivity

Keara KIRKNESS, *United Kingdom*

TROP2 as a potential therapeutic target in cholangiocarcinoma

Hanna ISELE, *Germany*

Cabozantinib-Induced Mitochondrial Activation of the cGAS-STING Pathway Enhances the Antitumor Immunity in Experimental Hepatocellular Carcinoma

Patricia RIDER, *Spain*

Impact of molecular alterations on outcomes of advanced biliary tract cancers treated with cisplatin, gemcitabine, and durvalumab: a multicenter, real-world study across Europe, Asia, and America

Federico ROSSARI, *Italy*

Final safety and efficacy results from the phase 1b/2a study of fostrox plus lenvatinib in second/third line patients with advanced hepatocellular carcinoma who progressed on immunotherapy

Jeffrey EVANS, *United Kingdom*

Inhibition of Strawberry Notch 1 represses hepatobiliary carcinoma development

Stephanie ROESSLER, *Germany*

Dissecting the role of tumor endothelial cells (ECs) and macrophages in hepatocellular carcinoma (HCC) with VETC+ angiogenesis provides potential targets of treatment

Camilla DE CARLO, *Italy*

Pattern of expression, immune contexture and clinical correlates of tertiary lymphoid structures (TLS) in biliary tract cancer (BTC)

Eleonora BORGHI, *Italy*

Breaking Barriers for Intensive Care Admission in Patients with Advanced HCC on Immunotherapy

Marta FORTUNY, *Spain*

Unveiling SLC2A3 upregulation in intrahepatic Cholangiocarcinoma: insight into metabolic reprogramming and patient prognosis

Michela Anna POLIDORO, *Italy*

Blocking RIPK3 impacts mitochondrial dynamics, endoplasmic reticulum stress and inflammation during murine chemical-induced hepatocarcinogenesis

André F. L. CARDADOR, *Portugal*

Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma

Paula OLAIZOLA, *United Kingdom*

The alpha-1 Pi*^{MZ} genotype is an independent risk factor for hepatocellular carcinoma development in patients with advanced chronic liver disease

Lorenz BALCAR, *Austria*

OGT and c-Myc promote non-canonical activation of gene expression by EZH2 in hepatocellular carcinoma

Mirjam ZEISEL, *France*

CRISPR/Cas9-Mediated BIRC5 Knockout Suppresses Proliferation and Migration while Promoting Apoptosis

Mahmoud ELHEFNAWI, *Egypt*

Thursday 20 February 2025

ePoster session 3

ePoster Area

17:00 - 17:30

Patterns of Extrahepatic Metastasis and Their Impact on Oncological Outcomes in HCC Patients Treated with Atezolizumab Plus Bevacizumab

Erwan VO QUANG, *Gambia*

Biopsy proteomic profiling predicts long-term HCC risk in patients with Metabolic dysfunction-Associated Steato-Hepatitis

Adele DELAMARRE, *France*

Metabolic liver cancer: Profiling and validation of epigenome-wide DNA methylation markers

Samuel ANTWI, *United States*

Preventing cholangiocarcinoma progression via a stromal dysregulation and an immune infiltration triggered by cold atmospheric plasma

Laura FOUASSIER, *France*

Leucine diet targeting leucyl-tRNA synthetase 1 enhances N-glycan biosynthesis translation and overcomes chemoresistance

Liu HAINING, *China*

Characterization of the peripheral lymphoid and myeloid compartments in hepatocellular carcinoma patients after combined immunotherapy

Pablo SAROBE, *Spain*

Short-period-related lifestyle changes significantly and long-lastingly impact HCC in MASLD via body composition modifications: a multicenter clinical study

Mario ROMEO, *Italy*

SHINE-UK a national evaluation of hepatocellular carcinoma surveillance and management

Christopher MYSKO, *United Kingdom*

Differential efficacy of irinotecan-based chemotherapy in distinct mouse strain backgrounds in cholangiocarcinoma models

Lisa WENDE, *Germany*

Pivotal role of Fibroblast growth factor 21 in protecting against liver injury and decelerating hepatocarcinogenesis by regulating oxidative stress response in non-steatotic liver disease

Hanna REDEKER, *Germany*

Blockade of CD73 expressed by hepatocellular tumour endothelium improves CD8+ T cell recruitment

Rosemary FAULKES, *United Kingdom*

Epigenetic regulation of liver endothelial cells as a novel target to boost immunotherapy efficacy in hepatocellular cancer

Saad REHMAN, *United Kingdom*

Machine learning for early detection of cholangiocarcinoma in a population-level cohort

Jan CLUSMANN, *Germany*

Role of post-translational modification (PTM) in liver cancer: HuR SUMOylation

Claudia M. REJANO-GORDILLO, *Spain*

Analysis of the peripheral immune context by single-cell transcriptomics in patients with hepatocellular carcinoma treated with immunotherapy

Beatriz MINGUEZ, *Spain*

DNA replication stress as a potential therapeutic target in hepatocellular carcinoma

Nina DESBOEUF, *Switzerland*

Targeting ATR to overcome cisplatin resistance in hepatoblastoma

Sandra REBOUSSOU, *France*

Sex shapes microbiota-epigenetics interplay in HCC development rewiring mitochondrial dynamics

Francesca GUERRIERI, *France*

Sorafenib combined with transarterial chemoembolization compared with sorafenib alone in advanced hepatocellular carcinoma (SELECT): a multicenter, phase 3, randomized, controlled trial

Guohong HAN, *China*

Machine and deep learning for non-invasive detection of esophageal varices in hepatocellular carcinoma patients

Asier RABASCO MENEGHETTI, *Germany*

The "A-B-C" cluster-based classification reveals distinct outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab

Claudia CAMPANI, *Italy*

The prognostic impact of comorbidities in patients with hepatocellular carcinoma: a multicenter observational study

Filippo PELIZZARO, *Italy*

The changing epidemiology of patients with HCC receiving a first-line systemic therapy: insights from ARPES and ARTE databases (2008-2024)

Lorenzo LANI, *Italy*

Thursday 20 February 2025

ePoster session 4 and Welcome Reception

ePoster Area

19:30 - 20:00

Prediction of nodal status on preoperative MRI for patients with intrahepatic cholangiocarcinoma: an apparent diffusion coefficient-based machine learning model

Flavio MILANA, *Italy*

Efficacy and safety of atezoliumab/bevacizumab for hepatocellular carcinoma in a real-world prospective cohort: a 2024 update

Bernardo STEFANINI, *Italy*

Circulating tumour DNA analysis for predicting clinical outcomes in advanced liver cancer: insights from tumor fraction, and DELFI score

Venkata Ramana MALLELA, *United Kingdom*

Development of liver cancer-derived organoids for drug screening and disease modelling

Silvia DE SIERVI, *Italy*

A Dynamic Contrast Enhanced Ultrasound Based Risk Prediction Model for the diagnosis of Hepatocellular Carcinoma in the grey area of CEUS-LI RADS: The PERSoN4 Model

Linda GALASSO, *Italy*

Diagnosis of extrahepatic cholangiocarcinoma in the presence of bile duct stricture using proteomic profiling: a proof-of-concept

Arthur MARICHEZ,

TLR3 and interferon gamma signaling synergistically increases drug efficacy in cholangiocarcinoma

Antonio T. PINTO, *Germany*

Characterization of hepatic lesions by LI-RADS during the surveillance of advanced liver disease in the prospective cohort of cases with congenital univentricular heart after Fontan palliation

Luisa CAVALLETTO, *Italy*

Data from a multinational registry on liver transplantation after immune checkpoint inhibition in hepatocellular carcinoma patients

Ulrike BAUER, *Germany*

Review of 20 years of liver tumor collection in the French liver biobank network

Bruno CLÉMENT, *France*

HIPERIA Study: Impact of clinically significant portal hypertension on the prognosis of patients with compensated cirrhosis and hepatocellular carcinoma undergoing systemic treatment

Antonio GUERRERO, *Spain*

Evaluating microbeam radiotherapy's effect on normal liver tissue: a step towards understanding its potential as a treatment

Cheuk Ting WU, *Switzerland*

Recapitulating the liver tumour endothelium in vitro: a tool for novel drug delivery studies

Megan BANNISTER, *United Kingdom*

Pattern of progression and post-progression survival in intermediate stage hepatocellular carcinoma. An analysis of the TACE 2 trial

Jack Shi Jie YUAN, *United Kingdom*

Annotation-free classification of liver cancer in whole slide images with multi-view feature representation-based one-way domain adaptation

Sunghong PARK, *Korea, Rep. of South*

Integrated Single-Cell RNA and Chromatin Accessibility profiling reveals epigenetic drivers of tumor heterogeneity in cholangiocarcinoma

Yoonhee JUNG, *Korea, Rep. of South*

High-resolution quantitative reconstruction of microvascular architectures in mouse hepatocellular carcinoma models

Haogang ZHAO, *China*

Prognostic Value of Imaging-Detected Immune-Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab

Dong Ho LEE, *Korea, Rep. of South*

Development of small molecule degrader of G1 to S phase Transition 1 (GSPT-1) for the hepatocellular carcinoma treatment

Andrew SAUNDERS, *Poland*

Proton-pump inhibitors and Gut Microbiome are Associated with Survival in Hepatocellular Carcinoma under Immunotherapy

Marco SANDUZZI ZAMPARELLI, *Spain*

Friday 21 February 2025

ePoster session 5

ePoster Area

10:30 - 11:00

Diagnosis of patients with fibrolamellar carcinoma: a Dutch nationwide study

Alicia FURUMAYA, *Netherlands*

ALBI grade and serum PIVKA-II changes during treatment drive clinical outcomes among atezolizumab-bevacizumab (ATZ/BEV) treated HCC patients with stable (SD) or progressive (PD) disease

Antonia SYRIHA, *Greece*

Delta hepatitis versus HBV mono-infection associated hepatocellular carcinoma: spot the difference

Mirela CHITUL, *Romania*

Leveraging normothermic liver machine perfusion as a platform to establish tumour directed ex-situ treatment

Felix Julius KRENDL, *Austria*

LEN-New FP as a promising second-line therapy for patients with unresectable hepatocellular carcinoma refractory to atezolizumab + bevacizumab, durvalumab + tremelimumab, and lenvatinib

Susumu MARUTA, *Japan*

Changes in incidence of primary liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in Scotland between 2000 and 2019

Berkay YANIK, *United Kingdom*

The efficacy of treatment for hepatocellular carcinoma in elderly patients

Han Ah LEE, *Korea, Rep. of South*

Investigation of GLI1 selective inhibitor for targeted therapy in Intrahepatic Cholangiocarcinoma: a step towards precision medicine

Savino PARADISO, *Italy*

Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death

Ciro CELSA, *Italy*

A tale of two cities: HCC surveillance inequalities in the United Kingdom

Maria QURASHI, *United Kingdom*

Somatic copy number alterations in circulating cell-free DNA as a predictive biomarker for hepatocellular carcinoma: insights from a proof-of-concept study

Elisa PINTO, *Italy*

Outcomes and safety of DAA treatment in HCV cirrhotic patients treated with Atezolizumab-Bevacizumab for hepatocellular carcinoma

Leonardo STELLA, *Italy*

Prognostic role of serum Glypican-3 measurement in patients with hepatocellular carcinoma

Marta GUARIGLIA, *Italy*

Impact of inhibiting the endoplasmic reticulum stress response on early carcinogenesis and Epithelial-mesenchymal transition in hepatocellular carcinoma

Jaafar KHALED, *Sweden*

Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma

Sara ASCARI, *Italy*

miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients

Clara VIANELLO, *Italy*

Lipid involvement in modeling macrophage phenotype in primary liver cancer

Barbara OLIVIERO, *Italy*

Clinical relevance in liver cancer patients and cholephilic characteristics of microbial bile acids conjugates

Rocio MACIAS, *Spain*

CD147 as a biomarker of hepatocellular carcinoma. Use of AV- CD147 extracellular vesicles as a diagnostic tool

Ángela ROJAS ÁLVAREZ-OSSORIO, *Spain*

MicroRNAs as promising therapeutic inhibitors of liver fibrosis and HCC

Asha BALAKRISHNAN, *Germany*

Friday 21 February 2025

ePoster session 6

ePoster Area

14:00 - 14:30

The study on effect of maternal obesity and trained immunity on the development of NAFLD in offspring

Moonhyung LEE, *Korea, Rep. of South*

Mitochondrial stress in patients with chronic hepatitis B-related hepatocellular carcinoma

Abdellah MANSOURI, *France*

Identification of Novel Extracellular Vesicle microRNA signatures in HepatoCellular Carcinoma patients with different cirrhotic aetiology (NEVER-HCC)

Rosanna VILLANI, *Italy*

Added-value of positron emission tomography imaging to alpha-fetoprotein score in predicting hepatocellular carcinoma recurrence after liver transplantation

Alina PASCALE, *France*

Prognostic factors for survival in patients with intermediate-stage unresectable hepatocellular carcinoma treated with lenvatinib or atezolizumab plus bevacizumab

Naoki UCHIHARA, *Japan*

Novel prooncogenic mechanism of ABCC3/B3H7 in liver metastasis using a hepatocellular cancer model

Cecilia ZERTUCHE-MARTÍNEZ, *Mexico*

Unveiling the Role of ZBED4 in Hepatocellular Carcinoma: Evidence From the Pan-cancer Analysis and Multiple Databases

Tongyu LIN, *China*

Durvalumab/Tremelimumab in real life: results of a prospective cohort

François VILLERET, *France*

Comparative Survival Analysis of Hepatocellular Carcinoma Patients With and Without Secondary Primary Tumors

Pompilia RADU, *Switzerland*

Association of Hyperglycemia and Outcomes after Hepatectomy for Hepatocellular carcinoma

Angelina EBNER, *Germany*

Statins in patients with advanced HCC treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from ARTE an Italian prospective multicentric dataset

Andrea DALBENI, *Italy*

Immune checkpoint inhibitors as adjunctive therapy with locoregional treatment in patients with advanced hepatocellular carcinoma is tolerable and improves disease-free survival: real-world experience

Tarek HASSANEIN, *United States*

¹⁸F-fluorodeoxyglucose positron emission tomography coupled with computed tomography (¹⁸F-FDG PET/CT) as a recurrence prognosis tool in liver transplantation for hepatocellular carcinoma

Olivier DETRY, *Belgium*

Clinical Characteristics and Outcomes for Hepatocellular Carcinoma with Extrahepatic Metastases

Wei-Lun TSAI, *Taiwan*

Real-world experiences of cabozantinib after immunotherapy in patients with unresectable HCC

Yuzuki TOKUNAGA, *Japan*

Evaluation of epidemiological trends and recurrence rates in unresectable hepatocellular carcinoma treated with microwave ablation: a 14-year study

Andrea MORMONE, *Italy*

Economic evaluation of the hepatocellular carcinoma early detection and treatment presidential initiative in Egypt

Mohamed ABDALLAH, *Egypt*

TACE combined with ICIs plus MTT after ¹²⁵I irradiation stent placement in patients with hepatocellular carcinoma and main portal vein tumor thrombosis (PATENCY II)

Junhao MEI, *China*

The ALBI score as a tool to optimise allocation to immunotherapy in patients with hepatocellular carcinoma: insights from a multicentre cohort

Birgit SCHWACHA-EIPPER, *Switzerland*

Updated Network Meta-Analysis of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: Consistent Role of TACE

Jihyun AN, *Korea, Rep. of South*

The evolving treatment landscape of advanced biliary cancer (ABC): a real-world overview of the last two decades

Eleonora BORGHI, *Italy*

Integrating machine learning and mathematical modeling to predict hepatocellular carcinoma recurrence and optimize outcomes after liver transplantation

Daniel SÁNCHEZ-TALTAVULL, *Switzerland*

16:45 - 17:15

Impact of MBOAT7 rs641738 polymorphism on prognosis of metabolic dysfunction-associated steatotic liver disease patients with hepatocellular carcinomaMarta GUARIGLIA, *Italy***Immune biomarkers and their network of connections in patients with hepatocellular carcinoma and liver cirrhosis associated with hepatitis C virus**Rosangela TEIXEIRA, *Brazil***Oncostatin M modulates the biology of cholangiocarcinoma cells and the tumor microenvironment**Nunzia PORRO, *Italy***Exploring the effectiveness of Machine Learning Algorithms in predicting Non-viral Hepatocellular Carcinoma (NVHCC) development: A Multicenter Cross-Sectional Study**Hend SHOUSHA, *Egypt***Real-World Analysis of Systemic Therapy Sequences After Atezolizumab and Bevacizumab in Hepatocellular Carcinoma: Insights from the IMMUreal Cohort**Florian P REITER, *Germany***Survival Outcome of Perioperative Radiotherapy in the Management of Cholangiocarcinoma**Alzahraa ALESAWY, *Egypt***Living Donor Liver Transplantation for HCC patients with Macroscopic Portal Vein Tumor Thrombosis**Volkan INCE, *Türkiye***Combinatorial effect of sorafenib, valproic acid and metformin in a fluorescent xenotransplant of hepatocellular carcinoma**Edgar Xchel FRANCO-JUÁREZ, *Mexico***Transarterial embolization with ethylene vinylalcol copolymer (EVOH) for spontaneous rupture of unresectable hepatocellular carcinoma: an oncological role beyond haemostasis?**Maria PARMIGIANI, *Italy***Stereotactic Radiotherapy as a Rescue Option for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation**PierLuigi ROMANO, *France***Improvement of quality of care and patient satisfaction for patients with hepatocellular carcinoma via implementation of a specialist nurse – interim analysis of the HCC-Care Nurse pilot study**Larissa PAJANCIC, *Austria***The good and the bad for patients with HCC in the pre and post COVID pandemic years**David BARNES, *United Kingdom***Alcohol etiology: a key factor in the management of hepatocellular carcinoma**

Anoisia COURTOIS, *France*

Preliminary results from the hellenic registry for intrahepatic cholangiocarcinomas

Dimitrios N. SAMONAKIS, *Greece*

The tumor burden score is a novel prognostic indicator for intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization: A preliminary single-center study

Merve GUZEL DIRIM, *Türkiye*

Prognosis of HCC in French Guiana and the French West Indies Compared to a Tertiary Center in the Île-de-France Region

Aloia ABOIKONI, *French Guiana*

Analysis of disease-specific therapeutic efficacy of atezolizumab plus bevacizumab in advanced hepatocellular carcinoma

Sae YUMITA, *Japan*

The Size - Growth Rate Relationship in Hepatocellular Carcinoma

Dhanushan GNANENDRAN, *United Kingdom*

Hepatic arterial infusion chemotherapy combined with camrelizumab and lenvatinib in the treatment of advanced hepatocellular carcinoma: a retrospective study

Wei DONG, *China*

EXTRAHEPATIC CHOLANGIOCARCINOMA LANDSCAPE IN ROMANIA

Raluca Maria STANCIULESCU, *Romania*

Predicting Hepatocellular Carcinoma in CHC patients using FIB4 and FIB6: A Longitudinal Study on non-invasive risk assessment models

Riham SOLIMAN, *Egypt*

Cholangiocarcinoma in Latin America: A Multicenter Observational Study Alerts on Ethnic Disparities in Tumor Presentation and Outcomes

Pedro Miguel RODRIGUES, *Spain*

Ethnic and racial disparities in hepatocellular carcinoma: “real-world” data from a Southern California clinic show worse outcomes in Hispanics/Latinos

Isabella MARTINEZ, *United States*

Saturday 22 February 2025

ePoster session 8

ePoster Area

10:00 - 10:30

Insights into the GALAD Score: a new optimal cut-off for hepatocellular carcinoma

Endrit SHAHINI, *Italy*

Early changes in body composition parameters following locoregional treatment are associated with survival and need for liver transplantation in cirrhotic patients with hepatocellular carcinoma

Simona PARISSA, *Italy*

Assessment of Immunotherapy alone (Atezolizumab/Bevacizumab) or combined with trans-arterial chemoembolization for treatment of intermediate stage-B3 Hepatocellular Carcinoma

Mirna ATEF LAMEY SHEHATA, *Egypt*

HCC is the leading indication for liver transplantation in HCV-infected patients in the direct-acting antivirals era (single centre experience)

Soňa FRAŇKOVÁ, *Czech Republic*

Hepatocyte Nuclear Factor 1 Alpha Variants as Risk Factor for Hepatocellular Carcinoma Development with and without Diabetes Mellitus

Mohamed ABDEL-SAMIEE, *Egypt*

Liquid Crystalline Nanoparticles based delivery of an Anticancer bioactive, Methotrexate

Saurabh BHARGAVA, *India*

M2BPGi associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis

Chi MAI, *Viet Nam*

Lenvatinib is highly effective in patients with hepatocellular carcinoma related to both non alcohol-related steatohepatitis and alcohol-related etiology: a propensity score analysis

Rodolfo SACCO, *Italy*

Data Mining Reveals Novel Gene Drivers of Lenvatinib Resistance in Hepatocellular Carcinoma

Cyrollah DISOMA, *Italy*

Setting the record straight: Utility and outcomes of HCV treatment in patients with HCV related HCC

Maria GUERRA VELOZ, *United Kingdom*

Real-world efficacy and safety of first-line Gemcitabine-Cisplatin-Immune Checkpoint Inhibitor in patients with advanced biliary tract cancers: a single-centre experience

Joycelyn LEE, *Singapore*

Enhancing liver biopsy accuracy with contrast-enhanced ultrasound: insights from Cracow University Hospital

Agnieszka CZAPSKA, *Poland*

Fibroscan role in determining the patients who are at high risk for developing HCC in 1000 cirrhotic Egyptian patients

Abdel Ghani Atef ABDEL GHANI BADRAN, *Egypt*

Advancing diagnostic adequacy and patient safety in liver lesions: The role of EUS-guided liver biopsy in modern oncology

Dilshad DHALIWAL, *United States*

Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: A single-center pilot study

Spyridon PANTZIOS, *Greece*

Effects of portal vein thrombosis on morbidity and mortality in hepatocellular carcinoma

Zülal İSTEMIHAN, *Türkiye*

KAIGI HCC – A web-based platform for discussion of hepatocellular carcinoma (HCC) treatment opportunities

Rainer GÜNTHER, *Germany*

Clinical and epidemiologic characteristics of patients with hepatocellular cancer in Sub-Saharan Africa: A five year single-center retrospective study

Yoseph BEZABIH, *Ethiopia*

Evaluation of the effect of 3'5-dimaleamylbenzoic acid on preneoplastic lesions in a model of chemical hepatocarcinogenesis

Karina GONZÁLEZ-GARCÍA, *Mexico*

High serum interleukin-6 and interleukin-8 levels are associated with tumor burden and poor prognosis in patients with hepatocellular carcinoma

Marta GUARIGLIA, *Italy*

Clinical characteristics and outcomes in patients diagnosed with hepatocellular carcinoma receiving resection or ablation in England

Betina BLAK, *United Kingdom*

Genetic variants in lipid metabolism and inflammation for HCC risk stratification and prognostication in MASLD

Jessica FUNCK, *France*

PO4-02 Personalized biomarkers scores outperform established scores in the short- and long-term prediction of hepatocellular carcinoma and decompensation

Erica VILLA, *Italy*

Saturday 22 February 2025

ePoster session 9

ePoster Area

11:45 - 12:15

Hepatitis delta virus (HDV) replication through HBV integrants in HCC recurrence after liver transplantation

Lorenza DI MARCO, *Italy*

FIB-4 in predicting hepatocellular carcinoma during viral hepatitis: A novel indication for an old tool

Myriam AYARI, *Tunisia*

Local control and recurrence patterns after stereotactic irradiation delivered in more than 4 fractions for hepatocellular carcinomas and liver metastases

Alizée RENAN, *France*

Tyrosine Kinase Inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients

Hend SHOUSHA, *Egypt*

Neoadjuvant chemotherapy as a tool of systemic control following portal vein embolization before major liver resection in patients with locally advanced intrahepatic cholangiocarcinoma

Mariia BILYCH, *Ukraine*

Treatment with combination transarterial chemoembolization and Lenvatinib plus sequential microwave ablation have improved the survival of Barcelona clinic livercancer stage B2 in Bangladesh

Ahmed Sarwar MURSHED, *Bangladesh*

Democratizing access to healthcare through Point of Care Testing (POCT)

Gavin HOOPER-NEWTON, *New Zealand*

Primary Clear cell adenocarcinoma of the liver and the risk of multiple primary gastrointestinal malignancies

belal HAMED, *Egypt*

Incidence and prevalence of hepatocellular carcinoma in patients coinfecting with HBV and HDV

Stefano LAVIOLA, *Italy*

Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma

Giuliana AMADDEO, *France*

The hepatocyte nuclear factor 1 homeobox A (HNF1A) gene polymorphism and AFP serum levels in Egyptian HCC patients

Mohamed ABDEL-SAMIEE, *Egypt*

A new machine learning-based algorithm to identify patients with hepatocellular carcinoma

Silvia CAGNIN, *Italy*

Mongolian liver cancer etiologic description analysis

Naranjargal DASHDORJ, *Mongolia*

Outcome associated prognostic factors in hepatocellular carcinoma patients undergoing resection: study of clinical, pathological, and serological aspects

Agnes SORIANO, *Spain*

The impact of various histopathological features and patient characteristics on the outcome of HCC patients: A population based study

Ahmed ALMEZAINI, *Egypt*

ALBI score as a predictor of survival in patients with hepatocellular carcinoma treated by transarterial radioembolization

Teresa FERRER, *Spain*

Assessing the impact of Body Mass Index on Hepatocellular Carcinoma survival following locoregional therapies

Adnan ALZANBAGI, *Saudi Arabia*

Real world data and outcomes of liver resection in patients with hepatocellular carcinoma

Mzamo MBELLE, *United Kingdom*

Urban and Rural Differences in Hepatocellular Carcinoma: A Retrospective Analysis from Southern Transylvania

Elena REZI, *Romania*

Short- And Long-Term Outcomes Of Surgery For Colorectal And Non-Colorectal Metastasis: A Report From University Hospital Center In Lithuania

Rokas JAGMINAS, *Lithuania*

Epidemiology of hepatocellular carcinoma (2016-2023). The epidemic of metabolic associated steatotic liver disease has not yet reached us
Andrés CASTANO-GARCIA, *Spain*